Cost-effectiveness analysis of combining traditional Chinese medicine in the treatment of hypertension: compound Apocynu
- PDF / 1,000,032 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 95 Downloads / 198 Views
(2020) 20:330
BMC Complementary Medicine and Therapies
RESEARCH ARTICLE
Open Access
Cost-effectiveness analysis of combining traditional Chinese medicine in the treatment of hypertension: compound Apocynum tablets combined with Nifedipine sustained-release tablets vs Nifedipine sustained-release tablets alone Qian Xu1†, Nan Yang1†, Shuang Feng1, Jianfei Guo2, Qi-bing Liu3* and Ming Hu1*
Abstract Background: We evaluated the long-term cost-effectiveness of antihypertensive traditional Chinese medicines (TCMs) and to compare the cost-effectiveness of a combined treatment consisting of compound Apocynum tablets and Nifedipine sustained-release tablets with the cost-effectiveness of treatment with Nifedipine sustained-release tablets alone. Methods: A Markov model was used to simulate the potential incremental cost-effectiveness per quality-adjusted life year (QALY) to be gained from compound Apocynum tablets and Nifedipine sustained-release tablets compared with Nifedipine sustained-release tablets alone. Model parameter estimates were informed by previously published studies. The direct medical costs of outpatients with hypertension were estimated from the health care provider’s perspective. A 5% annual discount rate was applied to both costs and QALYs. Results: TCMs combined with Nifedipine sustained-release tablets group generated a total 20-year cost of 11,517.94 RMB (US $1739.87), whereas Nifedipine sustained-release tablets alone group resulted in a 20-year cost of 7253.71 RMB (US $1095.73). TCMs combined with Nifedipine sustained-release tablets group resulted in a generation of 12.69 QALYs, whereas Nifedipine sustained-release tablets alone group resulted in 12.50. The incremental cost-utility ratio was 22, 443.32 RMB (US $3390.23) per QALY. Considering the threshold of 1 GDP per capita in China in 2018 (US $9764.95), the combination of compound Apocynum tablets and Nifedipine sustained-release tablets was a cost-effective strategy. One-way and probabilistic sensitivity analysis showed unchanged results over an acceptable range. (Continued on next page)
* Correspondence: [email protected]; [email protected] † Qian Xu and Nan Yang contributed equally to this work and are co-first authors. 3 Department of Pharmacology, School of Pharmaceutical Science, Hainan Medical University, Haikou, Hainan, China 1 West China School of Pharmacy Sichuan University, 17, Renmin South Road, 3rd Section, Chengdu 610041, Sichuan, China Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a
Data Loading...
